JPM Week, San Francisco, USA, 8-12 January 2024.

JPM Week brings the biotechnology and investment industry together for deal-making and networking meetings surrounding the annual J.P. Morgan Healthcare Conference in San Francisco.

BIO One-on-One Partnering™ unifies access to partnering for the entire life science industry and allows you to efficiently arrange meetings with biotechs, investors, in-licensors, medical device, medtech companies and other life science leaders at the San Francisco Marriott Marquis.

(December 2023)

BIO-Europe Spring, Barcelona, Spain, 18-20 March 2024.

Join us for Europe's largest springtime partnering event.

BIO-Europe Spring 2024 brings together the life science community for global deal making in-person and digitally. The event will take place in-person on March 18-20 in Barcelona, Spain, as well as digitally on March 26-27. Xplico will be present at both events.

(December 2023)

LSX World Congress, London, UK, 29-30 April 2024.

The 10th LSX World Congress is the leading partnering, strategy and investment event in Europe, with qualified 1:1 partnering at its core.

The event takes place on 29-30 April in London, UK, and brings together the CEOs and senior decision makers from the world's most innovative biopharma, medtech and healthtech companies with investors, senior BD&L teams, R&D leaders and industry KOLs.

(December 2023)

BIO International Convention, San Diego, USA, 3-6 June 2024.

Xplico will be present at BIO in San Diego, USA, in June 2024.

BIO International Convention unites a global network of business leaders, policymakers, investors and scientists for a common purpose: curing patients, protecting the planet, and nourishing humanity. Whether it’s across hemispheres or across the aisle, BIO brings the industry together to solve the most pressing issues facing our world.

(December 2023)

Xplico elected a Gazelle Company for the 4th year in a row

We are proud to announce that Xplico has been elected a Gazelle company for the 4th year in a row.

The election is organized by the Danish financial newspaper Børsen, and the requirements to become a Gazelle company are tough. A Gazelle business is continuously growing and, as a minimum, doubles its revenue or gross profit over four fiscal years, while maintaining positive growth throughout the years.

(October 2019)

Publication of the Xplico Valuation Survey

(November 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Finn Nikolajsen, gives his point of view on the challenges of the ownership structures that the biotech companies and their investors face when they try to analyze the consequences of current and future funding rounds and exits.

(October 2018)

Xplico article for Biotech & Money / LSX

In an article for Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, gives his point of view on the challenges that the Nordic life science companies face.

(August 2018)

Xplico Interview with Biotech & Money / LSX

In an interview with Biotech & Money / LSX – The Network For Life Science Executives, our partner, Uffe Boesen, explains how valuation is critical for strategic decision-making and points out to some of the common pitfalls companies encounter when using valuation models that are built in house.

(June 2018)